Tetraneuron described preclinical progress for TET‑101, an AAV‑based gene therapy targeting transcription factor E2F4 to prevent neuronal cell‑cycle re‑entry, proposing an 'upstream' approach to Alzheimer’s disease. Company leadership presented mechanistic rationale and preclinical efficacy at the European Cell & Gene Therapy Summit, positioning the program as distinct from amyloid‑ or tau‑directed strategies. Tetraneuron plans to pursue IND‑enabling studies with the aim of translating the upstream mechanism into human trials if safety and pharmacology profiles remain favorable.